Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Women's Studies, Pulmonary |
| Therapuetic Areas: | Oncology, Pulmonary / Respiratory Diseases, Reproductive |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2009 |
| End Date: | September 2012 |
A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold
This phase I single center open labeled study is planned to assess the safety and
tolerability of bevacizumab for treating patients with bilateral RRP. Approximately 20
patients will receive bevacizumab directly injected into the vocal folds. Patients who
enroll in the protocol will be injected with bevacizumab in one vocal fold that represents
the more diseased of the two folds. A sham injection with saline will be administered to the
other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for
6 months, with the same vocal fold selected for the initial treatment always getting the
drug injection. The investigator will also treat lesions by laser photoangiolysis of both
vocal folds using the 532 nm KTP laser.
We found this trial at
1
site
Click here to add this to my saved trials
